Introduction

26
The metabolic reprogramming of cancer has been observed for decades (Pavlova and Thompson, 2016; 27 Vander Heiden et al., 2009 ), yet whether this reprogramming is a general aspect of proliferation, an unintended 28 consequence of aberrant signaling pathways, or functionally involved in the oncogenic processes remains poorly 29 understood. Previous reports have examined numerous metabolic alterations, demonstrating that they support tumor 30 growth by meeting the energetic, biosynthetic, and redox needs of rapidly dividing cancer cells (Pavlova and 31 Thompson, 2016) . However, further examination has frequently shown that many of the same pathways are also 32 used by normal proliferating cells (Pearce and Pearce, 2013) , and therefore targeting these may not provide 33 therapeutic effects without unintended consequences. The liver is one of the few organs that have the capacity to 34 completely regenerate after partial resection. Thus, analysis of liver regeneration and oncogenesis provides a unique 35 opportunity to understand both benign and malignant proliferative processes, respectively. disease-free survival rates to remain dismal (Yang and Roberts, 2010) . Recent genetic profiling has shown that 42 HCCs display a preponderance of mutations affecting p53, the Wnt-β-catenin pathway, and the PI3K-AKT-mTOR 43 pathway (Ally et al., 2017; Schulze et al., 2015) . However, targeting these for effective preventive or therapeutic 44 interventions has remained difficult and largely unsuccessful. Thus, identification of additional factors or alternative 45 methods for intervention remains a high priority. In an attempt to identify targetable tumor-specific pathways, we 46 used unbiased comprehensive transcriptomic and metabolomic analyses to characterize human tumors, cancer cell 47 lines, and animal models of liver cancer and regeneration. 
Results
50
Progressive Loss of BCAA Catabolism in Hepatocellular Carcinoma Development and Progression
51
First, we analyzed a cohort of 48 HCC patients seen at Singapore General Hospital ( Figure S1A ). Transcriptomic 52 profiling and differential expression analysis of matching tumor and adjacent nontumor liver tissue samples returned 53 3624 significant genes ( Figure S1B ). To help focus the large gene set, as well as validate the findings and ensure 54 robustness, we compared expression changes to an independent, well-characterized HCC cohort from The Cancer 55 Genome Atlas (TCGA-LIHC) (Ally et al., 2017) . As expected, there was an overall direct correlation between the 56 prognostic utility of aggregating multiple (up to 5) genes identified the combined expression index of BCKDHA, 85 ACADS, and ACADSB as the most robust predictor of patient survival in both cohorts ( Figure 1J ). The bifurcation in 86 patient survival was most dramatic among high-grade tumors, with a 54-point difference in survival at 5 years (88% 87 versus 34%; Figure 1J ). Thus, the transcriptomic, enzymatic, and metabolomic analyses suggest that suppression of 88 catabolic enzymes in HCC spare the BCAAs from degradation, leading to their accumulation in tumors. The data 89 also suggest that the loss of BCAA catabolic enzyme expression in tumors is positively selected for during disease 90 progression, and that it has a significant impact on patient outcome. 
BCAA Catabolism is Suppressed in Tumors, but Not Regenerating Liver Tissues
93
Given that the metabolic needs of proliferating cancer cells are potentially similar to normal proliferating 94 hepatocytes, we questioned whether the suppression of BCAA catabolism was unique to tumors, or also observed in 95 liver regeneration. Thus, we examined multiple in vivo animal models and performed similar comprehensive 96 transcriptomic and metabolomic analyses. Tumor and nontumor tissues were harvested from animals administered 97 diethylnitrosamine (DEN), as this compound generates endogenous tumors resembling poor-prognosis HCC by 98 causing multiple stochastic DNA mutations in the liver (Heindryckx et al., 2009) . We also used the syngeneic 99 orthotopic Morris Hepatoma 3924a model to represent aggressive, fast-growing tumors. KEGG analysis of all 100 significant, differentially expressed genes shared among the tumor models confirmed that BCAA catabolism ranked 101 as the top pathway ( Figure S2A ). Importantly, BCAA catabolism remained the most significant pathway even after 102 omitting genes differentially expressed in proliferating hepatocytes after partial hepatectomy (Figures 2A, 2B and 103 S2B-F). Indeed, while tumors had reduced expression, regenerating tissues actually enhanced the expression of 104 BCAA catabolic enzymes modestly ( Figure 2C ). An initial non-targeted screen of over 200 metabolites identified 105 five that had accumulated in liver tumors with high significance, but not regenerating tissues, and among these were 106 all three BCAAs ( Figure S2G ). Subsequent targeted analyses confirmed that the BCAAs and only three other amino 107 acids (phenylalanine, methionine, and asparagine) had accumulated in both tumor models but not regenerating 108 tissues ( Figure 2D ). Accordingly, there was a significant decrease of downstream BCAA-derived metabolites (e.g.
109
C5:1 acylcarnitine) in tumors but not regenerating tissues ( Figure 2E ). 110 We next examined the protein levels and enzymatic activity of normal, tumor and regenerating liver tissues.
111
Of note, in addition to suppression of total protein levels, inhibition of BCKDH complex's activity can also be 112 achieved by phosphorylation of the BCKDHA subunit by the kinase BCKDK (Lynch and Adams, 2014; Shin et al., 113 2014). We observed that while Morris Hepatoma tumors had sharp reductions in total protein levels of the BCAA 114 catabolic enzymes, DEN-induced tumors displayed more overt changes in BCKDHA phosphorylation ( Figure 2F ). 115 Relative to normal (DEN-free) liver tissues, the phospho/total BCKDHA ratios were elevated in DEN-exposed pre-116 tumor tissues, and even further increased in tumors (Figures 2G and S2H) . Correspondingly, BCKDK was 117 overexpressed in pre-tumor and tumor tissues of the animal tumor models, as well as human HCC (Figures 2H and 118 S2I). BCKDH enzyme activity assays confirmed that regardless of the primary method of suppression, all animal 119 tumor tissues tested had significantly reduced catabolic capacity (Figures 2G and S2J) . Importantly, phospho/total 120 BCKDHA ratios, BCKDH activity, and BCKDK expression remained unchanged in regenerating tissues (Figures 121 2G and 2H) . Based on the concept of the ex vivo BCKDH assay, we also developed a hyperpolarized 13 C magnetic 122 resonance spectroscopy method (Lee et al., 2013) to quantify enzyme activity in vivo ( Figure 2I ). genes differentially expressed in liver cancers, in particular the BCAA catabolic enzymes ( Figure S3D ). ENCODE
144
ChIP-seq data also confirmed that PPARα bound to these promoters in the basal state ( Figure S3E ).
145
To further investigate expression changes, we examined a panel of human liver-derived cell lines. BCAAs significantly suppressed mTORC1 activity and proliferation rates of the HCC cell line Hep3B ( Figure 4C ).
186
In contrast to Kras-driven pancreatic cancer cells (Palm et al., 2015) , supplementing liver cancer cells with albumin or other protein sources (either alone or in combination with the mTOR inhibitors 188 Rapamycin or Torin 1) failed to rescue proliferation rates ( Figure S4D ). Similar to restricting the supply of BCAAs, 189 restoring expression of the BCAA catabolic enzymes BCKDHA, ACADS, or ACADSB also caused mTORC1 190 activity and cell proliferation to significantly decrease ( Figure 4D ). Hep3B cells with BT2 also caused a dose-dependent decrease in cell proliferation and mTORC1 activity ( Figure 4F ).
197
The suppression of mTORC1 activity and cell proliferation was also consistent across the panel of HCC cell lines, 198 and cell line sensitivity to BT2-mediated growth inhibition was analogous to Rapamycin and Torin 1 sensitivity 199 .
200
Removal of the nutrient sufficiency signal, such as after total amino acid withdrawal, causes mTOR to move 201 from an active, lysosomal localization to an inactive, diffuse cytosolic localization (Sancak et al., 2010) ( Figure 4H ).
202
We observed that BT2 treatment induced a similar dispersion of mTOR, suggesting it suppressed mTORC1 by high fat and/or BCAAs had a tumor incidence of 20-40% ( Figure 5A ). Moreover, of the tumors that did develop, the 219 largest were from mice fed high BCAA diets ( Figure 5B ). By 8 months post-injection, mice fed high BCAA diets 220 had a potent increase in both tumor number and size ( Figures 5D-F essential amino acids they cannot be completely removed long term; Table S1 ). All DEN-injected mice fed a low 247 BCAA diet survived the study duration, while this was true for only 70% of mice fed normal or high levels of 248 BCAAs ( Figure 6C ). Upon sacrifice, mice fed low BCAA diets also had significantly smaller tumors and reduced 249 liver BCAA content ( Figures 6D-6F ). Importantly, normal lean body mass and liver function was maintained in both 250 DEN-injected and control mice fed low BCAA diets J) . The effects of the high and low
251
BCAA diets were not due to differences in protein intake, as the tumor burden of mice fed diets adjusted for total 252 protein content were similar ( Figure 6J and adrenal cortex ( Figure 7C ). Moreover, the expression levels of numerous BCAA catabolic enzymes could be 268 used to robustly predict patient survival among these cancers ( Figure S6B ).
269
Recent reports have identified enhanced expression of the BCAT enzymes, which catalyze the reversible 270 transamination step, in some cancers (Hattori et al., 2017; Mayers et al., 2016; Raffel et al., 2017 with better outcome ( Figures 7D and S7A ). The remaining cancers had minimal difference in survival ( Figure S7A ).
294
Thus, when collectively analyzed them as a pan-cancer cohort, patients with higher tumor expression of BCKDHA,
295
ACADS, and ACADSB lived significantly longer (1849 days versus 732 days at 70% survival; Figure S7B ).
296
To determine if dietary intake of BCAAs correlated with cancer mortality in humans, we analyzed the 297 National Health and Nutrition Examination Survey (NHANES) III dataset with linked mortality data. In this cohort, 298 we calculated that the BCAAs comprised 17.3% of total protein intake. Given dietary recommendations for protein 299 at 10-35% of total kcal, we set the threshold for low BCAA intake at 1.73% (10% protein/total kcal x 17.3% 300 BCAA/total protein kcal). Few individuals consumed very high protein diets (>35% of total kcal), so we set the 301 threshold for high BCAA intake at 3.89%, which is at the median of recommended protein intake (22.5% 
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